DBS Initiates Coverage on EDGE MEDICAL-B with Buy Rating, Sets HK$68.1 Target Price

Stock News10:32

DBS has issued a research report initiating coverage on EDGE MEDICAL-B (02675) with a "Buy" rating and a target price of HK$68.1. The report forecasts an average annual compound profit growth rate of 187% for the period from 2026 to 2028. Additionally, revenue is projected to grow at a compound annual rate of 49% from 2026 to 2030, reaching RMB 4.3 billion. The bank anticipates that EDGE MEDICAL-B will achieve breakeven by 2026, driven by the key advantages of its core product, the MP1000. DBS identifies overseas markets as the primary growth driver for the company, which has currently obtained registration approvals in 55 countries and regions. However, it is noted that global tensions could potentially slow down the company's market penetration efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment